Terence Flynn
Stock Analyst at Morgan Stanley
(4.12)
# 454
Out of 4,667 analysts
171
Total ratings
55.17%
Success rate
11.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $231 → $224 | $167.76 | +33.52% | 13 | Nov 12, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $39 | $57.88 | -32.62% | 10 | Nov 12, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $130 → $123 | $97.44 | +26.23% | 14 | Nov 1, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $169 → $175 | $153.11 | +14.30% | 18 | Oct 16, 2024 | |
| BNTX BioNTech SE | Upgrades: Overweight | $93 → $145 | $102.14 | +41.96% | 1 | Sep 24, 2024 | |
| GPCR Structure Therapeutics | Initiates: Overweight | $118 | $32.71 | +260.75% | 1 | Sep 23, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $1,106 | $753.41 | +46.80% | 18 | Aug 27, 2024 | |
| BHVN Biohaven | Initiates: Overweight | $58 | $46.83 | +23.85% | 1 | Jul 24, 2024 | |
| ALMS Alumis | Initiates: Overweight | $36 | $9.64 | +273.44% | 1 | Jul 23, 2024 | |
| RPRX Royalty Pharma | Maintains: Overweight | $48 → $51 | $26.22 | +94.51% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $310 → $303 | $287.87 | +5.26% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $364.33 | -11.89% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $40 | $14.62 | +173.60% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $94.81 | +77.20% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $29 | $24.94 | +16.28% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $10 | $22.64 | -55.83% | 3 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $46 → $48 | $47.26 | +1.57% | 6 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $4.05 | +97.53% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $20 | $22.69 | -11.86% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $85 | $13.12 | +547.87% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $12 | $3.80 | +215.79% | 9 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $22 | $14.73 | +49.36% | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $156.00 | +179.49% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $248.79 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.35 | - | 1 | Jul 21, 2017 |
AbbVie
Nov 12, 2024
Maintains: Overweight
Price Target: $231 → $224
Current: $167.76
Upside: +33.52%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $57.88
Upside: -32.62%
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $130 → $123
Current: $97.44
Upside: +26.23%
Johnson & Johnson
Oct 16, 2024
Maintains: Equal-Weight
Price Target: $169 → $175
Current: $153.11
Upside: +14.30%
BioNTech SE
Sep 24, 2024
Upgrades: Overweight
Price Target: $93 → $145
Current: $102.14
Upside: +41.96%
Structure Therapeutics
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $32.71
Upside: +260.75%
Eli Lilly
Aug 27, 2024
Reiterates: Overweight
Price Target: $1,106
Current: $753.41
Upside: +46.80%
Biohaven
Jul 24, 2024
Initiates: Overweight
Price Target: $58
Current: $46.83
Upside: +23.85%
Alumis
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $9.64
Upside: +273.44%
Royalty Pharma
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $26.22
Upside: +94.51%
Jul 11, 2024
Maintains: Equal-Weight
Price Target: $310 → $303
Current: $287.87
Upside: +5.26%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $364.33
Upside: -11.89%
May 13, 2024
Maintains: Overweight
Price Target: $38 → $40
Current: $14.62
Upside: +173.60%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $94.81
Upside: +77.20%
May 2, 2024
Maintains: Equal-Weight
Price Target: $28 → $29
Current: $24.94
Upside: +16.28%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $22.64
Upside: -55.83%
Feb 26, 2024
Maintains: Underweight
Price Target: $46 → $48
Current: $47.26
Upside: +1.57%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $4.05
Upside: +97.53%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $22.69
Upside: -11.86%
Nov 13, 2023
Maintains: Overweight
Price Target: $90 → $85
Current: $13.12
Upside: +547.87%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $3.80
Upside: +215.79%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $27 → $22
Current: $14.73
Upside: +49.36%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $156.00
Upside: +179.49%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $248.79
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -